Join to View Full Profile
601 Elmwood AvenueBox 704Rochester, NY 14642
Phone+1 585-275-5853
Fax+1 585-273-1051
Dr. Hezel is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2006
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2000 - 2003
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2000
Certifications & Licensure
NY State Medical License 2009 - 2026
MA State Medical License 2002 - 2010
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer Start of enrollment: 2009 May 01
- Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer Start of enrollment: 2010 Dec 01
- PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Publications & Presentations
PubMed
- Total Neoadjuvant Therapy with FOLFOX Followed by Short-Course Radiation in Locally Advanced Rectal Cancer-An Alternative Approach Evaluated in a Single-Center Clinica...Janice Zhao, Andrea M Baran, Larissa K F Temple, Wenjia Wang, Jason Zittel
Journal of Clinical Medicine. 2026-04-22 - Phase 2 trial of exercise and low-dose ibuprofen for cancer-related cognitive impairment in patients receiving chemotherapy.Michelle C Janelsins, Riham A Alieldin, Tyler Holler, Hongying Sun, Po-Ju Lin
Cancer. 2026-04-15 - A Reassessment of the Clinical Utility ofGa-DOTATATE PET/CT in Patients With Gastroenteropancreatic Neuroendocrine Tumors.Orjola Prela, Brennen Caveney, Myla Strawderman, David Linehan, Eva Galka
Journal of Surgical Oncology. 2025-06-01
Journal Articles
- Germline Cancer Susceptibility Gene Variants, Somatic Second Hits, and Survival Outcomes in Patients with Resected Pancreatic CancerRichard F Dunne, Leona A Doyle, William C Hahn, Jason L Hornick, Andrea J Bullock, Sapna Syngal, Albert C Koong, Natalia Khalaf, Brian M Wolpin, Douglas A Rubinson, Da..., Nature
Press Mentions
Gene Mutations Drive Bile Duct CancerAugust 31st, 2022- Life-Threatening CostsNovember 11th, 2021
Study Points to Obesity as Driver of Pancreatic CancerApril 16th, 2020
Grant Support
- Genomic Instability And The Roles Of P53 And P19ARF In Pancreatic CancerNational Cancer Institute2009–2010
- Genomic Instability And The Roles Of P53 And P19ARF In Pancreatic CancerNational Cancer Institute2006–2008
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
